A Japanese man working for Astellas Pharma Inc. in China was taken into custody by Chinese authorities, and it has now been ...

Astellas Pharma's zolbetuximab – currently leading an expanding pack of drugs targeting claudin 18.2 – has shown efficacy in the first of a pair of phase 3 trials of gastric or ...

Astellas will pay $127.5 million up front to buy the remainder of the iota shares that it does not already own – the Japan-based pharma already has a stake after a US subsidiary invested in iota ...

Astellas Pharma and Yaskawa have agreed to form a JV that will focus on developing a cell therapy product manufacturing platform.

Astellas Pharma and Yaskawa Electric Corporation formalized a development deal signed last year that will see the two Japanese companies invest 3.5 billion Yen ($30.5 million) into developing an ...

Astellas Pharma (OTCPK:ALPMY) and YASKAWA Electric signed a definitive agreement to establish a joint venture for the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

(PRNewsFoto/Astellas Pharma Inc.) In the pharmaceutical industry, the commercialization of cell therapy faces many challenges stemming from the complex nature of the manufacturing process ...

Astellas Pharma and Yaskawa Electric have signed a definitive agreement to establish a joint venture aimed at advancing cell therapy manufacturing through automation. According to Astellas, the ...

Astellas Pharma and the Yaskawa Electric Corporation have agreed to form a joint venture (JV) that will focus on developing a cell therapy product manufacturing platform. The JV will leverage a ...